MONTRÉAL, Feb. 05, 2019 (GLOBE NEWSWIRE) — TERRANUEVA CORPORATION (“Terranueva” or the “Company”) announces the grant to its directors, officers, employees and consultants of an aggregate of 2,225,000 stock options to acquire the same number of common shares of the capital stock of the Corporation at an exercise price $0.50 per share for a period between 3 and 10 years, as the case may be.
Terranueva’s Business
The Corporation aspires to be at the forefront of research and development focused on therapeutic cannabis treatments. The principle mission of Terranueva is to enhance the lives of those who experience chronic pain, migraines, sleeping disorders or anxiety, through innovative approaches to cannabis-related treatment. Terranueva’s business vision is to produce cannabis to the highest standards in terms of effectiveness, quality and stability. As a technology driven company, we aim to develop the most sophisticated automated cannabis production system that will help to create traceability of our product and increase the yield of each of our strain to produce a premium quality product in the most efficient manner.
Learn more about Terranueva at terranueva.ca
CSE nor its regulation services provider (as that term is defined in its policies) accepts responsibility for the adequacy or accuracy of this news release.
For further information, please contact:
| For Terranueva Corporation : |
| Pierre Monet, Chief Financial Officer |
| Telephone : (514) 883-8733 |